EMAIL THIS PAGE TO A FRIEND

Urology

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.


PMID 24916669

Abstract

To explore explanations for the numerical imbalance of biopsy-detected Gleason 8-10 prostate cancers (PCa) diagnosed in years 3-4 in the dutasteride and placebo groups of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. REDUCE was a 4-year, randomized, double-blind, placebo-controlled trial of dutasteride (0.5xa0mg/d) vs placebo for PCa risk reduction. We modeled the incidence of Gleason 8-10 cancer and used logistic regression analysis to evaluate the effects of baseline predictors of PCa, as well as post-baseline prostate volume at the time of biopsy, on PCa diagnosis. We compared needle biopsy Gleason scores with corresponding surgery Gleason scores. All statistical tests conducted were 2-sided. Had there been a scheduled biopsy occurring only at year 4, we estimated a similar incidence of Gleason 8-10 PCa in the dutasteride (nxa0= 45) and placebo (nxa0= 46) groups. Two biopsy Gleason 7 cancers in the placebo group (nxa0= 150) were upgraded to Gleason 8-10 cancer on prostatectomy, and no patients in the dutasteride group (nxa0= 111) were upgraded. Logistic regression analysis demonstrated the effect of prostate volume on Gleason 8-10 cancer diagnosis. Although modeling of REDUCE data showed a similar incidence of Gleason 8-10 cancer in the dutasteride and placebo groups at year 4, an association between dutasteride and Gleason 8-10 cancer cannot be definitely excluded. It is likely that several biases, notably study design and prostate size at the time of biopsy, contributed to the numerical imbalance in Gleason 8-10 cancers observed between the treatment groups in years 3-4.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

Y0001598
Dutasteride, European Pharmacopoeia (EP) Reference Standard
C27H30F6N2O2